UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit

Pediatric cardiology, 2024-12, Vol.45 (8), p.1798-1803

2024

Volltextzugriff (PDF)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil

JHLT Open, 2024-11, Vol.6, p.100131, Article 100131

2024

Volltextzugriff (PDF)

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure

European journal of medical research, 2024-10, Vol.29 (1), p.479-7, Article 479

2024

Volltextzugriff (PDF)

Efficacy of brachytherapy versus radical prostatectomy for localized prostate cancer-propensity score-matched comparison

BMC cancer, 2024-09, Vol.24 (1), p.1177-8, Article 1177

2024

Volltextzugriff (PDF)

Idiopathic Pulmonary Fibrosis Treatment Market Size in the 7MM was ~USD 3,300 million in 2023, estimated DelveInsight

M2 Presswire, 2024-09-26

2024

Volltextzugriff (PDF)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA

PR newswire, 2024-09-25

2024

Volltextzugriff (PDF)

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

Business Wire, 2024-09-24

2024

Volltextzugriff (PDF)

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease

Life (Basel, Switzerland), 2024-09, Vol.14 (9), p.1203

2024

Volltextzugriff (PDF)

Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

M2 Presswire, 2024-09-16

2024

Volltextzugriff (PDF)

Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight

PR newswire, 2024-09-09

2024

Volltextzugriff (PDF)

Dr. Reddy's

Chain drug review, 2024-09, Vol.46 (11), p.62

2024

Volltextzugriff (PDF)

Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings

Business Wire, 2024-09-06

2024

Volltextzugriff (PDF)

Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings

PR newswire, 2024-09-05

2024

Volltextzugriff (PDF)

Neuraxial anesthesia for patients with severe pulmonary arterial hypertension undergoing urgent open abdominal surgeries: two case reports

JA clinical reports, 2024-09, Vol.10 (1), p.52-6, Article 52

2024

Volltextzugriff (PDF)

Mortality from pulmonary hypertension in Europe 2001-2019

BMC pulmonary medicine, 2024-08, Vol.24 (1), p.415-8, Article 415

2024

Volltextzugriff (PDF)

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Liquidia Corporation (LQDA)

Business Wire, 2024-08-27

2024

Volltextzugriff (PDF)

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost

Life (Basel, Switzerland), 2024-08, Vol.14 (9), p.1068

2024

Volltextzugriff (PDF)

Clinical outcome of lung transplantation for chronic thromboembolic pulmonary hypertension

BMC pulmonary medicine, 2024-08, Vol.24 (1), p.410-7

2024

Volltextzugriff (PDF)

LQDA Investors Have Opportunity to Join Liquidia Corporation Securities Fraud Investigation with the Schall Law Firm

Business Wire, 2024-08-19

2024

Volltextzugriff (PDF)

Interstitial Lung Disease Pipeline 2024 | Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, Pur

M2 Presswire, 2024-08-07

2024

Volltextzugriff (PDF)

Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management

International journal of molecular sciences, 2024-08, Vol.25 (15), p.8427

2024

Volltextzugriff (PDF)

Highlights on Future Treatments of IPF: Clues and Pitfalls

International journal of molecular sciences, 2024-08, Vol.25 (15), p.8392

2024

Volltextzugriff (PDF)

Quantification of treprostinil concentration in rat and human using a novel validated and rapid liquid chromatography-tandem mass spectrometry method: Experimental and clinical applications in ischemia–reperfusion injury

Clinica chimica acta, 2024-07, Vol.561, p.119837, Article 119837

2024

Volltextzugriff (PDF)

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Business Wire, 2024-07-10

2024

Volltextzugriff (PDF)

Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

M2 Presswire, 2024-07-09

2024

Volltextzugriff (PDF)

1 – 25 von 706

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(391)
Mit Volltextzugriff
(374)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Treprostinil
(644)
Science & Technology
(345)
Life Sciences & Biomedicine
(343)
Pulmonary Hypertension
(313)
Humans
(199)
Pulmonary Arterial Hypertension
(164)
Epoprostenol - Analogs & Derivatives
(152)
Pharmaceutical Industry
(123)
Hypertension, Pulmonary - Drug Therapy
(122)
Cardiovascular System & Cardiology
(121)
Female
(112)
Cardiac & Cardiovascular Systems
(111)
Male
(111)
Respiratory System
(107)
Epoprostenol
(103)
Pharmacology & Pharmacy
(99)
Epoprostenol - Administration & Dosage
(97)
Prostacyclin
(95)
Antihypertensive Agents - Administration & Dosage
(85)
Forecasts And Trends
(81)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(21)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure

Efficacy of brachytherapy versus radical prostatectomy for localized prostate cancer-propensity score-matched comparison

Idiopathic Pulmonary Fibrosis Treatment Market Size in the 7MM was ~USD 3,300 million in 2023, estimated DelveInsight

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease

Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight

Dr. Reddy's

Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings

Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings

Neuraxial anesthesia for patients with severe pulmonary arterial hypertension undergoing urgent open abdominal surgeries: two case reports

Mortality from pulmonary hypertension in Europe 2001-2019

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Liquidia Corporation (LQDA)

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost

Clinical outcome of lung transplantation for chronic thromboembolic pulmonary hypertension

LQDA Investors Have Opportunity to Join Liquidia Corporation Securities Fraud Investigation with the Schall Law Firm

Interstitial Lung Disease Pipeline 2024 | Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, Pur

Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management

Highlights on Future Treatments of IPF: Clues and Pitfalls

Quantification of treprostinil concentration in rat and human using a novel validated and rapid liquid chromatography-tandem mass spectrometry method: Experimental and clinical applications in ischemia–reperfusion injury

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Suchergebnisse filtern